Amplia Therapeutics Ltd - Amplia Receives Human Research Ethics Committee Clearance to Conduct Phase 1 Clinical Trial
Amplia Therapeutics Ltd (ASX:ATX)

Amplia Receives Human Research Ethics Committee Clearance to Conduct Phase 1 Clinical Trial

Published Sep 08, 2020

What happened?


What's happened?

Amplia Therapeutics Limited (ASX: ATX, "Amplia") has received clearance from the Alfred Hospital Human Research Ethics Committee (HREC) to conduct a Phase 1 clinical trial of its Focal Adhesion Kinase (FAK) inhibitor, AMP945, in healthy volunteers.

What are the key highlights?

  1. With this clearance in hand, Amplia expects to initiate its Phase 1 trial in the coming weeks with the first subject likely to be dosed by early October.
  2. The double blind, placebo-controlled Phase 1 trial is designed to establish the safety profile of oral doses of AMP945 in up to 64 healthy adult volunteers.
  3. Amplia is on track to complete dosing of subjects for the single ascending dose (SAD) component of the Phase 1 trial by the end of the year and have data from the completed trial in the first half of 2021.
  4. Data from this trial will be used to support Phase 2 clinical trials of AMP945 for the treatment of patients with specific, hard-to-treat cancers or with certain fibrotic diseases.

For further information, please refer to the announcement linked below.

CEO's summary

John Lambert CEO of Amplia Therapeutics Ltd has provided a statement.
John Lambert
John Lambert
CEO, Amplia Therapeutics Ltd

We are very excited to receive ethics approval for Amplia’s first clinical trial and to deliver on our commitment to advance AMP945 into human clinical trials during 2020. Despite the challenges thrown up by the current COVID-19 pandemic, in the past few months we have managed to secure two Orphan Drug Designations, complete the preclinical studies required to support the Phase 1 trial, secure funding to conduct the trial, and now receive the approval required to initiate the trial. We are extremely grateful for the support we have received from our partners, providers and shareholders that has allowed us get to this stage and initiate the first-in-human study for AMP945.”

Download Announcement

View this announcement as well as our full profile on the company.

Comments

Share your thoughts about this announcement...

Similar articles
Amplia Appoints Dr Mark Devlin as Chief Scientific Officer
What's happened? Amplia Therapeutics Limited (ASX: ATX, "Amplia") has announced that it has appointed Dr. Mark...
3 years ago
Amplia Appoints Nucleus Network to Conduct Phase 1 Clinical Trial
What's happened? Amplia Therapeutics Limited (ASX: ATX) has appointed the Nucleus Network in Melbourne to conduct its up...
3 years ago
Institutional Entitlement Offer Completed
What's happened? Amplia Therapeutics Limited (ASX: ATX, “Amplia”) has successfully completed the Institutional Entitleme...
3 years ago
Around the web
Amplia Therapeutics updates on next stage of ACCENT pancreatic cancer trial
Amplia Therapeutics (ASX:ATX) is progressing thee Phase 2a stage of the ACCENT trial involvi...
via biotechdispatch.com.au
Amplia Therapeutics takes step up in pancreatic cancer treatment
Amplia Therapeutics (ASX:ATX) has progressed its ACCENT trial to evaluate narmafotinib, a drug that...
via themarketonline.com.au
Check Up: Big week in world of biotech after these 2 Nasdaq stocks announce breakthroughs
Viking Therapeutics doubled after results of weight loss drug trial Janux Therapeutics tripled on p...
via stockhead.com.au
Powered by  
  • Company
    Amplia Therapeutics Ltd
  • Website
  • Sector
    Biotechnology
  • Industry
    Biotechnology
  • Code
    ASX:ATX
  • Socials
View Amplia Therapeutics Ltd's Profile

How do I invest?

Considering investing in Amplia Therapeutics Ltd?
Here's how to get started.
Low Cost Brokerage ASX Cheapest ASX Trading Platform
  1. 1

    Create account

    Open an account with an online broker of your choice. If you do not have an existing broker, consider Mawson Graham's A$9.50 flat fee platform.

    Sign up now »
  2. 2

    Search for ASX:ATX

    On your online investment platform search for the stock ticker code ASX:ATX to bring up the company's shares.

  3. 3

    Buy shares

    Place your order however you wish. If you need advice on buying or selling, you should seek the assistance of a full service financial adviser experienced in small cap equities.

Up